Kazia Therapeutics (ASX:KZA) see promising data from Phase 1 ovarian cancer trial

Company News

by Rachael Jones

Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.

Out of 16 patients, one patient demonstrated a complete response and two patients experienced a partial response according to industry-standard RECIST criteria, making an overall response rate of 19 per cent.

The patient who experienced a complete response remains in remission some three years after her last dose of Cantrixil.

Shares in Kazia Therapeutics (ASX:KZA) are trading 4.4 per cent higher at $1.42.

 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.